A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer

C. Erlichman, S. Fine, I. Kerr, W. Hoffmann, C. Gorg, H. J. Schmoll, P. Preusser, B. Thuerlimann, B. Gustavsson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1- leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity. Patients were treated with i.v. 5FU 370 mg/m2/day and 1-LV 100 mg/m2/day x 5 every 28 days. Toxicity and response were determined by WHO criteria. One hundred and twenty-six patients were entered, and 119 patients were eligible and evaluable. Eighty-eight patients had colon cancer and 37 had rectal cancer. The male:female ratio was 58:68. The mean age was 62.2 years. ECOGs performance status distribution was 0 (39.7%), 1 (46%), and 2 (11.9%). The median number of courses of therapy administered was 4.5. Severe- or life-threatening stomalitis or diarrhea, nausea, and granulocytopenia occurred in 17.6, 23.2, 17.6, and 15.9% of patients, respectively. The response rate was 22/119 [18.5%, 95% confidence interval (CI) of 12.0-26.6]. Median response duration was 188 days (95% CI of 111-248 days). Median survival was 379 days (95% confidence interval of 289- 452 days). These results indicate that when 1-LV is combined with 5FU. toxicity is similar in pattern and severity to that of the d1 recemic mixture. The overall efficacy of 1-LV + 5FU is comparable to a recent metaanalysis.

Original languageEnglish (US)
Pages (from-to)26-31
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number1
DOIs
StatePublished - Feb 1996

Fingerprint

Leucovorin
Fluorouracil
Colorectal Neoplasms
Confidence Intervals
Agranulocytosis
Survival
Rectal Neoplasms
Colonic Neoplasms
Nausea
Diarrhea

Keywords

  • 5FU
  • Colorectal metastasis Phase II
  • Leucovorin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. / Erlichman, C.; Fine, S.; Kerr, I.; Hoffmann, W.; Gorg, C.; Schmoll, H. J.; Preusser, P.; Thuerlimann, B.; Gustavsson, B.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 19, No. 1, 02.1996, p. 26-31.

Research output: Contribution to journalArticle

Erlichman, C, Fine, S, Kerr, I, Hoffmann, W, Gorg, C, Schmoll, HJ, Preusser, P, Thuerlimann, B & Gustavsson, B 1996, 'A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 19, no. 1, pp. 26-31. https://doi.org/10.1097/00000421-199602000-00006
Erlichman, C. ; Fine, S. ; Kerr, I. ; Hoffmann, W. ; Gorg, C. ; Schmoll, H. J. ; Preusser, P. ; Thuerlimann, B. ; Gustavsson, B. / A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1996 ; Vol. 19, No. 1. pp. 26-31.
@article{05999ebbf2f24e1dba7a0e4a4ec35dcb,
title = "A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer",
abstract = "We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1- leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity. Patients were treated with i.v. 5FU 370 mg/m2/day and 1-LV 100 mg/m2/day x 5 every 28 days. Toxicity and response were determined by WHO criteria. One hundred and twenty-six patients were entered, and 119 patients were eligible and evaluable. Eighty-eight patients had colon cancer and 37 had rectal cancer. The male:female ratio was 58:68. The mean age was 62.2 years. ECOGs performance status distribution was 0 (39.7{\%}), 1 (46{\%}), and 2 (11.9{\%}). The median number of courses of therapy administered was 4.5. Severe- or life-threatening stomalitis or diarrhea, nausea, and granulocytopenia occurred in 17.6, 23.2, 17.6, and 15.9{\%} of patients, respectively. The response rate was 22/119 [18.5{\%}, 95{\%} confidence interval (CI) of 12.0-26.6]. Median response duration was 188 days (95{\%} CI of 111-248 days). Median survival was 379 days (95{\%} confidence interval of 289- 452 days). These results indicate that when 1-LV is combined with 5FU. toxicity is similar in pattern and severity to that of the d1 recemic mixture. The overall efficacy of 1-LV + 5FU is comparable to a recent metaanalysis.",
keywords = "5FU, Colorectal metastasis Phase II, Leucovorin",
author = "C. Erlichman and S. Fine and I. Kerr and W. Hoffmann and C. Gorg and Schmoll, {H. J.} and P. Preusser and B. Thuerlimann and B. Gustavsson",
year = "1996",
month = "2",
doi = "10.1097/00000421-199602000-00006",
language = "English (US)",
volume = "19",
pages = "26--31",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer

AU - Erlichman, C.

AU - Fine, S.

AU - Kerr, I.

AU - Hoffmann, W.

AU - Gorg, C.

AU - Schmoll, H. J.

AU - Preusser, P.

AU - Thuerlimann, B.

AU - Gustavsson, B.

PY - 1996/2

Y1 - 1996/2

N2 - We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1- leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity. Patients were treated with i.v. 5FU 370 mg/m2/day and 1-LV 100 mg/m2/day x 5 every 28 days. Toxicity and response were determined by WHO criteria. One hundred and twenty-six patients were entered, and 119 patients were eligible and evaluable. Eighty-eight patients had colon cancer and 37 had rectal cancer. The male:female ratio was 58:68. The mean age was 62.2 years. ECOGs performance status distribution was 0 (39.7%), 1 (46%), and 2 (11.9%). The median number of courses of therapy administered was 4.5. Severe- or life-threatening stomalitis or diarrhea, nausea, and granulocytopenia occurred in 17.6, 23.2, 17.6, and 15.9% of patients, respectively. The response rate was 22/119 [18.5%, 95% confidence interval (CI) of 12.0-26.6]. Median response duration was 188 days (95% CI of 111-248 days). Median survival was 379 days (95% confidence interval of 289- 452 days). These results indicate that when 1-LV is combined with 5FU. toxicity is similar in pattern and severity to that of the d1 recemic mixture. The overall efficacy of 1-LV + 5FU is comparable to a recent metaanalysis.

AB - We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1- leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity. Patients were treated with i.v. 5FU 370 mg/m2/day and 1-LV 100 mg/m2/day x 5 every 28 days. Toxicity and response were determined by WHO criteria. One hundred and twenty-six patients were entered, and 119 patients were eligible and evaluable. Eighty-eight patients had colon cancer and 37 had rectal cancer. The male:female ratio was 58:68. The mean age was 62.2 years. ECOGs performance status distribution was 0 (39.7%), 1 (46%), and 2 (11.9%). The median number of courses of therapy administered was 4.5. Severe- or life-threatening stomalitis or diarrhea, nausea, and granulocytopenia occurred in 17.6, 23.2, 17.6, and 15.9% of patients, respectively. The response rate was 22/119 [18.5%, 95% confidence interval (CI) of 12.0-26.6]. Median response duration was 188 days (95% CI of 111-248 days). Median survival was 379 days (95% confidence interval of 289- 452 days). These results indicate that when 1-LV is combined with 5FU. toxicity is similar in pattern and severity to that of the d1 recemic mixture. The overall efficacy of 1-LV + 5FU is comparable to a recent metaanalysis.

KW - 5FU

KW - Colorectal metastasis Phase II

KW - Leucovorin

UR - http://www.scopus.com/inward/record.url?scp=0030048024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030048024&partnerID=8YFLogxK

U2 - 10.1097/00000421-199602000-00006

DO - 10.1097/00000421-199602000-00006

M3 - Article

C2 - 8554031

AN - SCOPUS:0030048024

VL - 19

SP - 26

EP - 31

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 1

ER -